Inogen CEO to Participate in Investor Forum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy INGN?
Source: Newsfilter
- Virtual Investor Forum: Inogen, Inc.'s CEO Kevin Smith will participate in the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 17, 2026, at 3:00 p.m. Eastern Time, showcasing the company's leadership in the medical technology sector.
- Live Webcast and Recording: The event will provide a live audio webcast and archived recording through Inogen's Investor Relations website, ensuring that all interested parties can access relevant information, thereby enhancing the company's transparency and investor communication.
- Innovative Respiratory Products: Inogen focuses on developing and marketing innovative respiratory therapy devices for homecare, aiming to improve the quality of life for patients with chronic respiratory conditions, which highlights its competitive advantage in the medical technology market.
- Forward-Looking Statements: The company notes that all non-historical statements are forward-looking and subject to various risks and uncertainties, emphasizing a cautious approach towards future business plans and market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INGN
Wall Street analysts forecast INGN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.820
Low
12.00
Averages
13.00
High
14.00
Current: 6.820
Low
12.00
Averages
13.00
High
14.00
About INGN
Inogen, Inc. is a global medical technology company offering respiratory products for use in the homecare setting. The Company partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products available. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators (POCs), used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. It also distributes the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure (CPAP) masks in the United States. Its proprietary Inogen One and Inogen Rove POC systems concentrate the air around the patient to offer a source of supplemental oxygen 24 hours a day, seven days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inogen Shares Surge 6.9% Driven by Buy Rating
- Price Surge Reason: Inogen (INGN) shares rose 6.9% in the last trading session to $6.8, with trading volume significantly above average, indicating increased investor interest in the stock.
- Buy Rating Impact: The initiation of a “Buy” rating by Freedom Broker, along with a substantial price target, has attracted new investors, driving the stock's rise and reflecting market confidence in the company's future growth.
- Governance Improvement Signal: The appointment of industry veteran Vafa Jamali to the board and a cooperation agreement with activist shareholder Kent Lake signal stronger strategic alignment and execution oversight, further boosting market confidence.
- Earnings Forecast: Inogen is expected to report a quarterly loss of $0.24 per share, representing a 4% year-over-year change, with revenues projected at $82.4 million, up 0.2%, reflecting the company's stability and potential growth in the medical instruments sector.
See More
Inogen CEO to Participate in Healthcare Conference
- Conference Participation: Inogen, Inc.'s CEO Kevin Smith will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, showcasing the company's leadership in respiratory products and attracting investor and industry attention.
- Live Webcast: The conference will feature a live audio webcast and archived recording available on Inogen's Investor Relations website, ensuring that all interested parties can access relevant information, thereby enhancing company transparency and investor trust.
- Information Disclosure: Inogen intends to continue using its Investor Relations website as a means of disclosing material non-public information, complying with Regulation FD, which ensures compliance and enhances the company's image.
- Company Background: Inogen is a leading global medical technology company focused on developing and marketing innovative respiratory therapy devices for patients with chronic respiratory conditions, committed to improving patient quality of life and expanding market share.
See More
Inogen Appoints New CFO to Support Growth Strategy
- Executive Change: Inogen has appointed Jason Richardson as Chief Financial Officer effective April 6, 2026, replacing Michael Bourque, who will remain in an advisory role until June 30, 2026, to ensure a smooth transition.
- Experienced Leadership: Prior to joining Inogen, Richardson served as CFO at Baxter International, and his extensive experience in financial management is expected to provide crucial support for Inogen's financial strategy.
- Growth Objectives: Inogen aims for a 6% revenue growth in 2026 while launching a $30 million share repurchase program, intending to enhance shareholder value and boost market confidence.
- Market Reaction: This executive change and growth plan may positively impact Inogen's stock price, reflecting the company's strategic adjustments and forward-looking positioning in the face of market challenges.
See More
Inogen CEO to Participate in Investor Forum
- Virtual Investor Forum: Inogen, Inc.'s CEO Kevin Smith will participate in the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 17, 2026, at 3:00 p.m. Eastern Time, showcasing the company's leadership in the medical technology sector.
- Live Webcast and Recording: The event will provide a live audio webcast and archived recording through Inogen's Investor Relations website, ensuring that all interested parties can access relevant information, thereby enhancing the company's transparency and investor communication.
- Innovative Respiratory Products: Inogen focuses on developing and marketing innovative respiratory therapy devices for homecare, aiming to improve the quality of life for patients with chronic respiratory conditions, which highlights its competitive advantage in the medical technology market.
- Forward-Looking Statements: The company notes that all non-historical statements are forward-looking and subject to various risks and uncertainties, emphasizing a cautious approach towards future business plans and market opportunities.
See More
Inogen Reports Q4 2025 Earnings with Strategic Growth Insights
- Revenue Growth: Inogen reported approximately $82 million in total revenue for Q4 2025, with nearly $349 million for the full year, reflecting a 4% year-over-year growth and successfully meeting its mid-single-digit growth target for 2025, indicating stable market performance.
- International Business Highlight: The international segment delivered $32.5 million in revenue for Q4, representing a 15% year-over-year increase, marking it as a bright spot in the company's results and underscoring the importance of international expansion for long-term growth.
- New Product Launch: The company initiated a limited market release of Simeox in the U.S. and is nearing completion of a clinical study in China, expected to support a commercial launch in the second half of the year, thereby enhancing its product portfolio and market competitiveness.
- Share Repurchase Program: The Board of Directors authorized a $30 million share repurchase program intended for execution over 2026 and 2027, aimed at enhancing shareholder value and reflecting management's confidence in the company's future growth prospects.
See More
Inogen Set to Release Q4 Earnings on February 24
- Earnings Announcement: Inogen (INGN) is scheduled to announce its Q4 earnings on February 24 after market close, with market participants keenly awaiting the results, which could have a short-term impact on the stock price.
- Earnings Expectations: The consensus EPS estimate stands at -$0.18, reflecting a significant year-over-year improvement of 56.1%, indicating a potential enhancement in the company's profitability that may boost investor confidence.
- Revenue Forecast: The anticipated revenue for Q4 is $82 million, representing a modest year-over-year growth of 2.4%, which, while limited, demonstrates the company's stability in the market and may attract inflows from investors seeking reliable returns.
- Performance Consistency: Over the past year, Inogen has consistently beaten both EPS and revenue estimates 100% of the time, and this track record of exceeding expectations could further bolster market confidence in its future performance.
See More
Inogen Shares Surge 6.9% Driven by Buy Rating
- Price Surge Reason: Inogen (INGN) shares rose 6.9% in the last trading session to $6.8, with trading volume significantly above average, indicating increased investor interest in the stock.
- Buy Rating Impact: The initiation of a “Buy” rating by Freedom Broker, along with a substantial price target, has attracted new investors, driving the stock's rise and reflecting market confidence in the company's future growth.
- Governance Improvement Signal: The appointment of industry veteran Vafa Jamali to the board and a cooperation agreement with activist shareholder Kent Lake signal stronger strategic alignment and execution oversight, further boosting market confidence.
- Earnings Forecast: Inogen is expected to report a quarterly loss of $0.24 per share, representing a 4% year-over-year change, with revenues projected at $82.4 million, up 0.2%, reflecting the company's stability and potential growth in the medical instruments sector.
See More
Inogen CEO to Participate in Healthcare Conference
- Conference Participation: Inogen, Inc.'s CEO Kevin Smith will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, showcasing the company's leadership in respiratory products and attracting investor and industry attention.
- Live Webcast: The conference will feature a live audio webcast and archived recording available on Inogen's Investor Relations website, ensuring that all interested parties can access relevant information, thereby enhancing company transparency and investor trust.
- Information Disclosure: Inogen intends to continue using its Investor Relations website as a means of disclosing material non-public information, complying with Regulation FD, which ensures compliance and enhances the company's image.
- Company Background: Inogen is a leading global medical technology company focused on developing and marketing innovative respiratory therapy devices for patients with chronic respiratory conditions, committed to improving patient quality of life and expanding market share.
See More
Inogen Appoints New CFO to Support Growth Strategy
- Executive Change: Inogen has appointed Jason Richardson as Chief Financial Officer effective April 6, 2026, replacing Michael Bourque, who will remain in an advisory role until June 30, 2026, to ensure a smooth transition.
- Experienced Leadership: Prior to joining Inogen, Richardson served as CFO at Baxter International, and his extensive experience in financial management is expected to provide crucial support for Inogen's financial strategy.
- Growth Objectives: Inogen aims for a 6% revenue growth in 2026 while launching a $30 million share repurchase program, intending to enhance shareholder value and boost market confidence.
- Market Reaction: This executive change and growth plan may positively impact Inogen's stock price, reflecting the company's strategic adjustments and forward-looking positioning in the face of market challenges.
See More
Inogen CEO to Participate in Investor Forum
- Virtual Investor Forum: Inogen, Inc.'s CEO Kevin Smith will participate in the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 17, 2026, at 3:00 p.m. Eastern Time, showcasing the company's leadership in the medical technology sector.
- Live Webcast and Recording: The event will provide a live audio webcast and archived recording through Inogen's Investor Relations website, ensuring that all interested parties can access relevant information, thereby enhancing the company's transparency and investor communication.
- Innovative Respiratory Products: Inogen focuses on developing and marketing innovative respiratory therapy devices for homecare, aiming to improve the quality of life for patients with chronic respiratory conditions, which highlights its competitive advantage in the medical technology market.
- Forward-Looking Statements: The company notes that all non-historical statements are forward-looking and subject to various risks and uncertainties, emphasizing a cautious approach towards future business plans and market opportunities.
See More
Inogen Reports Q4 2025 Earnings with Strategic Growth Insights
- Revenue Growth: Inogen reported approximately $82 million in total revenue for Q4 2025, with nearly $349 million for the full year, reflecting a 4% year-over-year growth and successfully meeting its mid-single-digit growth target for 2025, indicating stable market performance.
- International Business Highlight: The international segment delivered $32.5 million in revenue for Q4, representing a 15% year-over-year increase, marking it as a bright spot in the company's results and underscoring the importance of international expansion for long-term growth.
- New Product Launch: The company initiated a limited market release of Simeox in the U.S. and is nearing completion of a clinical study in China, expected to support a commercial launch in the second half of the year, thereby enhancing its product portfolio and market competitiveness.
- Share Repurchase Program: The Board of Directors authorized a $30 million share repurchase program intended for execution over 2026 and 2027, aimed at enhancing shareholder value and reflecting management's confidence in the company's future growth prospects.
See More
Inogen Set to Release Q4 Earnings on February 24
- Earnings Announcement: Inogen (INGN) is scheduled to announce its Q4 earnings on February 24 after market close, with market participants keenly awaiting the results, which could have a short-term impact on the stock price.
- Earnings Expectations: The consensus EPS estimate stands at -$0.18, reflecting a significant year-over-year improvement of 56.1%, indicating a potential enhancement in the company's profitability that may boost investor confidence.
- Revenue Forecast: The anticipated revenue for Q4 is $82 million, representing a modest year-over-year growth of 2.4%, which, while limited, demonstrates the company's stability in the market and may attract inflows from investors seeking reliable returns.
- Performance Consistency: Over the past year, Inogen has consistently beaten both EPS and revenue estimates 100% of the time, and this track record of exceeding expectations could further bolster market confidence in its future performance.
See More
